 |
 |
|
|
|
| Tirzepatide |
 |
| no |
 |
| 2023788-19-2 |
 |
Tirzepatide is a novel medication that is FDA approved for the treatment of type 2 diabetes mellitus.Given its potent weight loss properties,buy tirzepatide be used off-label for obesity treatment.
It works as a dual GLP-1 agonist and GIP agonist to maximize similar benefits that are seen with GLP-1 medications such as semaglutide.It is currently implemented as a second-line diabetes medication,similar to GLP-1 medications,and given as a once-a-week subcutaneous injectable.The FDA approved peptide Tirzepatide in May 2022.
Benefits:
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist,which is FDA-approved for treating type 2 diabetes mellitus.It is important to note that tirzepatide is not approved for treating type-1 diabetes mellitus and has not been studied in patients with pancreatitis.Tirzepatide is a GIP receptor and GLP-1 receptor agonist,leading to significantly improved glycemic control in type 2 diabetics and significant weight reduction. |
 |
medical use
|
 |
| no |
|
|
|
 |
 |
|
AASraw/Aea.ltd
|
| 전화번호 |
+13204026693 |
| 팩스번호 |
|
| 홈페이지 |
- |
| 이메일 |
King@aea.ltd
|
| 주소 |
FLAT/RM C1 4/F SUMMIT BUILDING 30 MAN YUE STREET HUNG HOM,HONG KONG,CHINA |
|
 |
|
|
|
|
|
|
|
|
